This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bebear, C. M.
Right arrow Articles by Bebear, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bebear, C. M.
Right arrow Articles by Bebear, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2557-2560, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activity of Trovafloxacin Compared to Those of Five Antimicrobials against Mycoplasmas Including Mycoplasma hominis and Ureaplasma urealyticum Fluoroquinolone-Resistant Isolates That Have Been Genetically Characterized

C. M. Bebear,1,* H. Renaudin,1 A. Charron,1 D. Gruson,1 M. Lefrancois,2 and C. Bebear1

Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex,1 and Laboratoire Pfizer, 91400, Orsay,2 France

Received 28 December 1999/Returned for modification 28 April 2000/Accepted 12 June 2000

The in vitro activity of trovafloxacin against 125 strains of Mycoplasma species and Ureaplasma urealyticum, including fluoroquinolone-susceptible and fluoroquinolone-resistant species, was compared to those of other fluoroquinolones, doxycycline, and erythromycin. The MIC at which 90% of isolates are inhibited for all fluoroquinolone-susceptible strains was 0.25 µg/ml. Whatever the associated mutations, trovafloxacin exhibited greater activity than the other fluoroquinolones tested against fluoroquinolone-resistant Mycoplasma hominis and U. urealyticum isolates.


* Corresponding author. Mailing address: Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux cedex, France. Phone: (33) 5.57.57.16.25. Fax: (33) 5.56.93.29.40. E-mail: cecile.bebear{at}u-bordeaux2.fr.


Antimicrobial Agents and Chemotherapy, September 2000, p. 2557-2560, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Beeton, M. L., Chalker, V. J., Kotecha, S., Spiller, O. B. (2009). Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism. J Antimicrob Chemother 64: 529-538 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2009). Comparative In Vitro Susceptibilities of Human Mycoplasmas and Ureaplasmas to a New Investigational Ketolide, CEM-101. Antimicrob. Agents Chemother. 53: 2139-2141 [Abstract] [Full Text]  
  • Beeton, M. L., Chalker, V. J., Maxwell, N. C., Kotecha, S., Spiller, O. B. (2009). Concurrent Titration and Determination of Antibiotic Resistance in Ureaplasma Species with Identification of Novel Point Mutations in Genes Associated with Resistance. Antimicrob. Agents Chemother. 53: 2020-2027 [Abstract] [Full Text]  
  • Geissdorfer, W., Sandner, G., John, S., Gessner, A., Schoerner, C., Schroppel, K. (2008). Ureaplasma urealyticum Meningitis in an Adult Patient. J. Clin. Microbiol. 46: 1141-1143 [Abstract] [Full Text]  
  • Duffy, L., Glass, J., Hall, G., Avery, R., Rackley, R., Peterson, S., Waites, K. (2006). Fluoroquinolone Resistance in Ureaplasma parvum in the United States. J. Clin. Microbiol. 44: 1590-1591 [Abstract] [Full Text]  
  • Bebear, C. M., Renaudin, H., Charron, A., Clerc, M., Pereyre, S., Bebear, C. (2003). DNA Gyrase and Topoisomerase IV Mutations in Clinical Isolates of Ureaplasma spp. and Mycoplasma hominis Resistant to Fluoroquinolones. Antimicrob. Agents Chemother. 47: 3323-3325 [Abstract] [Full Text]  
  • Neumayr, L., Lennette, E., Kelly, D., Earles, A., Embury, S., Groncy, P., Grossi, M., Grover, R., McMahon, L., Swerdlow, P., Waldron, P., Vichinsky, E. (2003). Mycoplasma Disease and Acute Chest Syndrome in Sickle Cell Disease. Pediatrics 112: 87-95 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Bing, X., Duffy, L. B. (2003). In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 161-165 [Abstract] [Full Text]  
  • Reinhardt, A. K., Kempf, I., Kobisch, M., Gautier-Bouchardon, A. V. (2002). Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level. J Antimicrob Chemother 50: 589-592 [Abstract] [Full Text]  
  • Reinhardt, A. K., Bebear, C. M., Kobisch, M., Kempf, I., Gautier-Bouchardon, A. V. (2002). Characterization of Mutations in DNA Gyrase and Topoisomerase IV Involved in Quinolone Resistance of Mycoplasma gallisepticum Mutants Obtained In Vitro. Antimicrob. Agents Chemother. 46: 590-593 [Abstract] [Full Text]  
  • Deguchi, T., Maeda, S.-I., Tamaki, M., Yoshida, T., Ishiko, H., Ito, M., Yokoi, S., Takahashi, Y., Ishihara, S. (2001). Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother 48: 742-744 [Full Text]  
  • Bébéar, C. M., Grau, O., Charron, A., Renaudin, H., Gruson, D., Bébéar, C. (2000). Cloning and Nucleotide Sequence of the DNA Gyrase (gyrA) Gene from Mycoplasma hominis and Characterization of Quinolone-Resistant Mutants Selected In Vitro with Trovafloxacin. Antimicrob. Agents Chemother. 44: 2719-2727 [Abstract] [Full Text]